4.8 Article

Optimization of PAMAM-gold nanoparticle conjugation for gene therapy

Journal

BIOMATERIALS
Volume 35, Issue 5, Pages 1725-1734

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.11.026

Keywords

Gold; Nanoparticle; Nanocomposite; Gene therapy; Dendrimer; DNA

Funding

  1. Ford Foundation
  2. Keck Center of the Gulf Coast Consortia
  3. Nanobiology Interdisciplinary Graduate Training Program
  4. National Institute of Biomedical Imaging and Bioengineering (NIBIB) [T32EB009379]
  5. Medical Scientist Training Program at Baylor College of Medicine
  6. Edward and Josephine Hudson Scholarship
  7. Ruth L Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD Fellows [F30CA165686-01A1]
  8. National Institute of Health (NIH) and National Cancer Institute (NCI)
  9. Welch Foundation [C-1598]
  10. NIH [R01 CA172836]

Ask authors/readers for more resources

The development of efficient and biocompatible non-viral vectors for gene therapy remains a great challenge, and exploiting the properties of both nanoparticle carriers and cationic polymers is an attractive approach. In this work, we have developed gold nanoparticle (AuNP) polyamidoamine (PAMAM) conjugates for use as non-viral transfection agents. AuPAMAM conjugates were prepared by crosslinking PAMAM dendrimers to carboxylic-terminated AuNPs via EDC and sulfo-NHS chemistry. EDC and sulfo-NHS have been utilized widely and in numerous applications such as amino acid coupling; however, their use in the coupling of PAMAM dendrimers to AuNPs presents new challenges to form effective and stable constructs for delivery that have not yet been examined. Enhanced colloidal stability and DNA condensation ability was established by probing two critical synthetic parameters: the reaction rate of the PAMAM crosslinking step, and the amine to carboxyl ratio. Based on this work, increasing the amine to carboxyl ratio during conjugation of PAMAM onto AuNPs yielded the optimal vector with respect to colloidal stability and transfection efficiency in vitro. AuPAMAM conjugates present attractive candidates for non-viral gene delivery due to their commercial availability, ease of fabrication and scaleup, high yield, high transfection efficiency and low cytotoxicity. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available